Paul Durham, PhD: Noninvasive Vagus Nerve Stimulation
The distinguished professor and director of cell biology at Missouri State University discussed the findings of a model of nVNS which suggested it operates through a novel mechanism compared to available migraine therapies.
“What we found is that when we put inhibitors of the serotonin receptors, the 5HT3 or 5HT7, that we could basically block the inhibitory effect of the vagus nerve, which actually then provides evidence that this is a completely novel mechanism. It’s different than a lot of the anti-migraine drugs that are currently on the market.”
At the
NeurologyLive sat with Durham to find out more about the study’s findings and how this intervention differs from what’s currently available to patients. He explained that the team injected complete Freund’s adjuvant (CFA) at 10 rat neck muscle sites to induce inflammation in the model, and then exposed them to either the aroma of California bay leaf oil extract or sodium nitroprusside. Either stimulation administered in 1 ms pulses at 5 kHz, repeated at 25 Hz for 2 minutes at a pair of 5-minute intervals, or sumatriptan delivered subcutaneously at a dose of 0.3 mg/kg.
Noninvasive vagus nerve stimulation was approved by the FDA in January 2018, based on data from the PRESTO trial (NCT02686034), which showed consistent and significantly better pain relief at both 30 and 60 minutes (P <.03). Additionally, it showed a decrease of pain intensity at 30, 60, and 90 minutes, as well as a reduction in rescue medicine.2
For more coverage of AHS 2019,
REFERENCE
1. Durham P. Noninvasive Vagus Nerve Stimulation Inhibits Trigeminal Nociception in Two Episodic Migraine Models by Enhancing Descending Pain Modulation. Presented at: 2019 American Headache Society Annual Meeting. July 11-14, 2019; Philadelphia, PA. Session OR07.
2. Tassorelli C, Grazzi L, de Tommaso M, et al; PRESTO Study Group. Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology. 2018;91:e364-e373.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Perispinal Etanercept Shows No Efficacy in Treating Chronic Stroke
September 16th 2025
- Current Challenges and New Opportunities Ahead for Women in Neurology
September 15th 2025
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025